contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


newbury-pharmaceuticals-has-entered-into-a-new-partnership-for-prucalopride-tablets

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Newbury Pharmaceuticals är verksamt inom läkemedelsbranschen. Bolaget utvecklar en pipeline av egenutvecklade och licensierade produkter med fokus på specialläkemedel inom områden som onkologi, sällsynta sjukdomar och neurologi. Bolaget bedriver sin verksamhet inom den skandinaviska marknaden. Newbury Pharmaceuticals grundades år 2020 och har sitt huvudkontor i Lund.

Newbury Pharmaceuticals

Newbury has signed a contract with a new partner to register and launch Prucalopride in Sweden. Prucalopride, 1 and 2 mg tablets, is a selective, high affinity 5-HT4 receptor agonist which targets...

<div class="mfn-preamble"><p><strong>Newbury has signed a contract with a new partner to register and launch Prucalopride in Sweden. Prucalopride, 1 and 2 mg tablets, is a selective, high affinity 5-HT4 receptor agonist which targets the impaired motility associated with chronic constipation, thus normalizing bowel movements.</strong></p></div><div class="mfn-body"><blockquote><em>“With the addition of prucalopride, we have established a strategic partnership with a multinational pharmaceutical company recognized for its advanced R&amp;D capabilities, global regulatory approvals, and presence across major healthcare markets worldwide. This collaboration not only strengthens our portfolio today but also provides a basis for bringing additional products to market in the future, supporting our ambition to become the local champion and partner of choice,” says Mr. Karl Karlsson, CEO of Newbury.</em></blockquote><p>Regulatory approval is expected in the near future, with a planned launch in Sweden later this year.</p></div><div class="mfn-footer mfn-contacts mfn-e2b1977b3686"><p><strong class="mfn-heading-1">For more information, contact:</strong></p><hr><p>Karl Karlsson, CEO<br><a href="mailto:karl.karlsson@newburypharma.com" rel="noopener">karl.karlsson@newburypharma.com</a><br>Mobile: +46 46 12 11 20</p><p><a href="http://www.newburypharma.com/" rel="noopener">www.newburypharma.com</a></p></div><div class="mfn-footer mfn-about mfn-488d133b85e8"><p><strong class="mfn-heading-1">About Newbury Pharmaceuticals</strong></p><hr><p>Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and an extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.</p><p>Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a class="mfn-generated mfn-primary" href="https://storage.mfn.se/2ce8c7a5-bf9e-47ea-bc9b-eaba244026d0/newbury-pharmaceuticals-has-entered-into-a-new-partnership-for-prucalopride-tablets.pdf" rel="noopener">Newbury Pharmaceuticals has entered into a new partnership for Prucalopride tablets</a></p></div>

Newbury Pharmaceuticals has entered into a new partnership for Prucalopride tablets

Finanslingo enkelt förklarat: EBIT, EBITA och EBITDA 

Finansiella nyckeltal: EV/EBIT, EV/EBITA, EV/EBITDA och EV/Sales

Return on capital (ROE, ROI, ROIC, RONIC)

Iran-krisens effekter på råvaru- och aktiemarknaderna

Dollarns dominans – ohotad eller sårbar?  Om dollarns position som världsvaluta 